- Home
- STRRP vs CGEN Comparison
STRRP vs CGEN Comparison
Compare STRRP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRRP
- CGEN
- Stock Information
- Founded
- STRRP N/A
- CGEN 1993
- Country
- STRRP United States
- CGEN Israel
- Employees
- STRRP 194
- CGEN N/A
- Industry
- STRRP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STRRP Health Care
- CGEN Health Care
- Exchange
- STRRP Nasdaq
- CGEN Nasdaq
- Market Cap
- STRRP N/A
- CGEN 167.4M
- IPO Year
- STRRP N/A
- CGEN 2000
- Fundamental
- Price
- STRRP $9.23
- CGEN $1.59
- Analyst Decision
- STRRP
- CGEN
- Analyst Count
- STRRP 0
- CGEN 0
- Target Price
- STRRP N/A
- CGEN N/A
- AVG Volume (30 Days)
- STRRP N/A
- CGEN 155.0K
- Earning Date
- STRRP N/A
- CGEN 08-05-2025
- Dividend Yield
- STRRP N/A
- CGEN N/A
- EPS Growth
- STRRP N/A
- CGEN N/A
- EPS
- STRRP N/A
- CGEN N/A
- Revenue
- STRRP N/A
- CGEN $27,589,000.00
- Revenue This Year
- STRRP N/A
- CGEN N/A
- Revenue Next Year
- STRRP N/A
- CGEN $173.80
- P/E Ratio
- STRRP N/A
- CGEN N/A
- Revenue Growth
- STRRP N/A
- CGEN N/A
- 52 Week Low
- STRRP N/A
- CGEN $1.13
- 52 Week High
- STRRP N/A
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- STRRP 55.69
- CGEN 44.35
- Support Level
- STRRP $9.01
- CGEN $1.66
- Resistance Level
- STRRP $9.29
- CGEN $1.74
- Average True Range (ATR)
- STRRP 0.03
- CGEN 0.10
- MACD
- STRRP 0.03
- CGEN -0.02
- Stochastic Oscillator
- STRRP 82.86
- CGEN 8.00
About STRRP Star Equity Holdings Inc. Series A Cumulative Perpetual Preferred Stock
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.